

1011

THE ROLE OF TYPE I GROWTH FACTOR RECEPTORS IN HUMAN CANCER

W.J. Gullick

ICRF Oncology Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN, U.K.

Several lines of evidence support the hypothesis that growth factor receptor overexpression is a contributory factor to cell transformation. Equally, overexpression represents a target for new therapeutic agents. Conceptually, these may be either directed at reducing receptor activity or designed to exploit overexpression relative to normal tissues. Monoclonal antibodies to growth factor receptors have been developed which take advantage of the latter phenomenon. We have made an antibody to c-erbB-3 which has been employed in ADEPT in a preclinical model of tumour growth inhibition. We have also prepared antibodies to the type III mutant EGF receptor found commonly in glioblastoma multiforme. Their specificity and tumour localisation *in vivo* has been explored. These represent an ideal model system as they are directed against a tumour specific antigen expressed at very high levels on brain tumours.

1012

EGF-RELATED PEPTIDES IN CANCER

D.S. Salomon

Tumor Growth Factor Sect., Lab. Tumor Immunology & Biology, NCI, NIH, Bethesda, MD, U.S.A.

Epidermal growth factor (EGF), transforming growth factor α (TGF α), amphiregulin (AR), heparin-binding EGF (HB-EGF), betacellulin (BTC), heregulin (HGR), epiregulin, and cripto-1 (CR-1) belong to a large family of structurally and functionally related peptides. With the exception of HRG and CR-1, these peptides bind to and activate the EGF tyrosine kinase (c-erb) receptor which is a member of the type I receptor tyrosine kinase family. HRG can bind to two other type I tyrosine kinase receptors, c-erb B-3 and c-erb B-4 which can in turn heterodimerize with c-erb B-2. All of these peptides are mitogens for normal and malignant epithelial cells. Also, these peptides can modulate various aspects of cell differentiation. The expression of these peptides is differentially regulated during early development in the mouse. Hormones such as 17 β -estradiol, progesterone, androgens, thyroxine and angiotensin can enhance the expression of TGF α , AR, HB-EGF and EGF in a tissue specific manner. The expression of TGF α , AR and HRG can also be upregulated by various oncogenes such as an activated c-Ha-ras gene or by overexpression of c-erb B-2. An autocrine role has been formally demonstrated for TGF α , AR and/or HB-EGF in oncogene transformed mammary epithelial cells, in transformed keratinocytes and in several different human breast, colon, gastric, lung and pancreatic carcinoma cell lines. TGF α and CR-1 can function as dominant transforming genes in mammary epithelial cells and in keratinocytes. This is supported by the observation that TGF α transgenic mice have a high incidence of developing hepatocellular carcinomas, mammary carcinomas and gastric and pancreatic dysplasias. The expression of TGF α , AR, HRG and CR-1 has been detected at an elevated level and frequency in primary human glioblastomas, bladder, breast, cervical, colon, esophageal, gastric, hepatic, lung, ovarian, pancreatic and prostate carcinomas and in premalignant bladder, breast, cervical, colon and gastric lesions.

1013

ONCOGENES AND ONCO-SUPPRESSOR GENES AS PROGNOSTIC INDICATORS IN HUMAN CANCER

D.A. Spandidos

Medical School, University of Crete, Heraklion, Greece

Recent progress in the field of oncogenes and onco-suppressor genes has produced valuable information concerning the molecular and cellular biology of the cancer cell and its implication in clinical oncology. Some oncogenes such as *ras*, *myc* and *erbB-2* and the onco-suppressor gene *p53* have been extensively investigated in the progression of carcinogenesis in several types of human tumors. *Ras* mutations have been found to occur frequently in variety of cancers and *p53* mutations are the most common genetic abnormality found in all neoplasias. In certain cases the incidence of aberrant gene expression and genetic alterations of oncogenes and onco-suppressor genes have been shown to be important in the progression of these cancers and may be of use as prognostic indicators and form the basis for a successful therapy.

1014

TYPE I RECEPTOR TYROSINE KINASES AS TARGETS FOR CANCER THERAPY

N.E. Hynes, R. Beerli, D. Graus-Porta, W. Weiss

Friedrich Miescher Institute, P.O. Box 2543, 4002 Basel, Switzerland

The Type I family of receptor tyrosine kinases (RTK) has four members: EGFR, ErbB-2, ErbB-3 and ErbB-4. Interest in these proteins is high since altered expression of the receptors has been implicated in the development of human cancer. We have taken two approaches to inhibit growth of tumor cells using ErbB-2 and EGFR as targets. First, genes encoding single-chain antibodies (scFv) were expressed intracellularly in tumor cell lines. scFvs represent the smallest high affinity binding domain of an antibody. The scFvs were provided with an N-terminal hydrophobic leader and a C-terminal KDEL ER retention signal. Expression of the ErbB-2 specific scFv FRP5 in ErbB-2 transformed cells prevents transit of the receptor through the ER and its appearance on the plasma membrane. This results in functional inactivation of the receptor and reversion of the transformed phenotype. Second, we have used recombinant DNA technology to produce scFv-toxin fusion proteins which specifically bind ErbB-2 and EGFR. The scFv-encoding sequences were joined to a cDNA encoding a truncated *Pseudomonas* exotoxin A (ETA) protein. A TGF α -ETA fusion protein has also been produced. The bacterial produced recombinant proteins bind with high affinity to the appropriate receptor and display potent *in vitro* and *in vivo* cytotoxic effects selective for tumor cells expressing ErbB-2 or EGFR.

1015

RECURRENT REARRANGEMENTS IN THE MAG LOCUS IN A VARIETY OF BENIGN MESENCHYMAL TUMORS

W.J.M. Van de Ven¹, H.F.P.M. Schoenmakers¹, S. Wanschura², R. Mois¹, H. Van den Berghe¹, J. Bullerdiek²

¹Center for Human Genetics, University of Leuven, Belgium

²University of Bremen, Germany

Translocations involving human chromosome segment 12q13-q15 have been observed in a variety of benign solid tumors. Among these are subgroups of uterine leiomyoma, lipoma, and pieomorphic adenoma of the salivary glands. In recent molecular cytogenetic studies, the chromosome 12 breakpoints of these three tumor types were found to cluster in a 1.7 Mb breakpoint region, which was designated MAR (Multiple Aberration Region). Subsequent studies indicated that the majority of the chromosome 12 breakpoints in these tumors mapped within a 445 kb subregion of MAR. Furthermore, evaluation of other mesenchymal tumors with aberrations involving chromosome segment 12q14-q15, such as hamartoma of the lung, hamartoma and fibroadenoma of the breast, and angiomatoma, revealed that in these tumors the 445 kb subregion of MAR was also directly affected, which might point towards a common genetic denominator; e.g. a multiple aberrant growth (*MAG*) gene. Using a positional cloning approach, we identified a candidate *MAG* gene within a 175 kb segment of MAR and characterized its genomic organization. By FISH, we pinpointed within this gene the majority of the breakpoints of the seven different benign solid tumor types. By Southern blot and 3'-RACE analysis, we demonstrated consistent rearrangements in *MAG* and/or expression of altered *MAG* transcripts. Implications will be discussed.

1016

INVOLVEMENT OF NF2 GENE ALTERATIONS IN TUMORIGENESIS

G. Thomas

INSERM U434, Institut Curie, 75231 Paris Cedex 05, France

Neurofibromatosis type 2 (NF2) is a monogenic dominantly inherited disease characterized by a susceptibility to develop nervous system tumors, particularly schwannomas and meningiomas. The genetic defect causing NF2 has been shown to map to chromosome 22q12. The gene which when mutated causes NF2 was isolated in 1993. Point mutations in the constitutional DNA of affected individuals can be found in over a third of the patients. Frequent, somatic mutations in sporadic or familial schwannomas and meningiomas were also found. They were frequently associated with loss of the other NF2 allele. Thus functional inactivation of the NF2 gene by a two hit mechanism is expected to operate in the tumorigenic process of both schwannomas and meningiomas, strongly suggesting that NF2 may be a tumor suppressor gene. Mutations in the NF2 gene were rare or absent in the other tumor types tested with the notable exception of mesothelioma recently reported by Sekido *et al.* The NF2 gene codes for a product called schwannomin (also merlin) which has significant homology with proteins known to link membrane

proteins and cytoskeleton suggesting that it may play a role in transducing a signal from the cell membrane to the nucleus.

1017

MUTATIONS THAT ALTER THE FUNCTION OF GROWTH REGULATING GENES IN HUMAN BREAST CANCER

M.A.J. van Dijk, A.N. Floore, L.J. van 't Veer

The Netherlands Cancer Institute, Amsterdam, The Netherlands

Elevated levels of estrogen receptors (ER) are found in sixty percent of breast carcinoma and correlate with a better prognosis when patients are treated with antiestrogens. However, forty percent of the patients with an ER positive tumor do not respond to this treatment. Recent findings suggest that variant estrogen receptors may be present in these tumors that are non-functional or non-responsive, or on the contrary are responsive to antiestrogens. The expression of ER is routinely measured either by immunohistochemical staining or by a radioactive ligand binding assay, but neither method is suitable to detect variant receptors with altered function. We have developed a rapid functional screening method in yeast, that allows us to determine the prevalence and functional activity of variant estrogen receptors among normal receptors. The assay can discriminate between constitutively active, inactive and inducible ER variants.

The functional integrity of p53 tumor suppressor gene has been related to radiation or chemotherapy response. We are testing the functional activity of p53 of breast carcinoma also in a yeast growth assay. Frequently detected point mutations in p53 have all been associated with functional inactivation of the protein.

Testing functional activity of genes may prove to be of greater importance in predicting the outcome of therapy than merely analyzing their presence and may lead to improved treatment selection for breast cancer patients.

1018

CYTOGENETICS OF MESENCHYMAL TUMORS

F. Mitelman

University of Lund, Sweden

The cytogenetic information on solid tumors is in many respects only fragmentary and for many tumor types the knowledge is extremely limited. Furthermore, most solid tumors are characterized by very complex karyotypes which means that it is practically impossible to distinguish the pathogenetically relevant aberrations from the confusing variety of seemingly random changes that accumulate during tumor progression. In spite of all these shortcomings, an increasing number of characteristic and even specific karyotypic changes have been identified in both benign and malignant tumors of different histologic subtypes. Several of these aberrations, in particular those found in malignant mesenchymal tumors, have been characterized at the molecular level, e.g., t(12;16)(q13;p11) in myxoid liposarcoma, t(2;13)(q35;q14) in alveolar rhabdomyosarcoma, t(X;18)(p11;q11) in synovial sarcoma, t(11;22)(q24;q12) in Ewing's sarcoma, Askin's tumor and peripheral neuroepithelioma, t(12;22)(q13;q12) in clear cell sarcoma of tendons and aponeurosis, and t(11;22)(p13;q12) in the desmoplastic small round cell tumor. All these aberrations lead to the generation of fusion genes and result in the formation of presumably tumorigenic chimeric proteins.